PET/CT AND PAEDIATRIC ONCOLOGY: A SINGLE CENTRE EXPERIENCE A. Cistaro 1, L. Gastaldo 2, A. Brach del Prever 3, V. Arena 1, E. Pelosi 1, M. Mancini 1 CONCLUSIONS.

Slides:



Advertisements
Similar presentations
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Advertisements

PET/CT in Oncology George Segall, M.D. Stanford University.
The Thyroid Incidentaloma
How to Manage High Risk Myeloma Dr Matthew Jenner Consultant Haematologist Southampton General Hospital UK Myeloma Forum Autumn Day 12 November 2014.
Medicare Transmittal 956 CR 5124 May 19, 2006 NOPR Billing Instruction Clarification – Physician Offices/IDTF use QR Modifier – Hospitals use QR and V70.7.
What every parent should know about cancer.. Early Warning Signs of Cancer in Children 1. A child who is very pale and is bleeding. 2. A child with persistent.
ROLE OF FDG-PET/CT STUDY IN THE DETECTION OF BONE MARROW DISEASE IN PATIENTS WITH AGGRESSIVE NON- HODGKIN LYMPHOMA (NHL) AND HODGKIN LYMPHOMA (HL) Figure.
18F- FDG PET/CT in the Diagnosis of Tumor Thrombosis
Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.
EBUS-TBNA reduces the number of mediastinoscopies for the staging of lung cancer with more than fifty percent Background Methods Results Conclusion Niels.
In The Nam of God.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Brain Scan Imaging MRI, CAT, PET Imaging Interpreting Functions of the Brain through Imaging – Activity Case Study – Professional Sports and Head Trauma.
Application of Positron Emission Tomography ( PET ) in Colorectal Cancer Dr Chan Wai Keung Department of Surgery Ruttonjee and Tang Shiu Kin Hospitals.
Silent but deadly – how to spot a sarcoma
AN INTRODUCTION TO PET-CT SCANNING Ray Murphy Chair – MCCN Partnership Group.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.
PET/CT & PET/MRI Radiopharmacy
PET after Chemotherapy in Rhabdomyosarcoma Connective Tissue Oncology Society November 19, 2005 Michelle L. Klem, Leonard H. Wexler, Ravinder Grewal, Heiko.
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
TUMOURS OF NASAL CAVITY & PARANASAL SINUSES
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
How to manage suspected cancer
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Dual-time point 18F-FDG PET/CT scan: is it always working?
1 Positron Emission Tomography Center IRMET S.p.A., Turin, ITALY 2 Institute of Cognitive Sciences and Technologies, Rome, ITALY 3 ALS Center, Department.
PET Applications in Oncology
HYBRID IMAGING.  Combination  Nuclear medicine  Radiology  PET/CT  Positron emission tomography  Computed tomography  SPECT/CT  Single photon.
Incidence of Childhood Cancer. What is cancer ? Uncontrolled growth of cells Are these cancer cells abnormal? No, but their behaviour is.
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.
radio-iodinated metaiodobenzylguanidine (123I-MIBG)
Tumour And Tumour Like Conditions of Bone l benign tumours are common l the most common malignant bone tumour are secondary metastasis l second most common.
18 FDG PET/CT in the diagnosis of Malignant Peripheral Nerve Sheath Tumours VS Warbey, RE Ferner, JT Dunn, E Calonje, MJ O’Doherty St Thomas’ Clinical.
PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Follow up in Chest Tumors : Value of integrated PET/CT By : Dr. Heba Nabil, MSc Radiology Specialist at Nasser Institute For Research and Treatment.
Ostoesarcoma By: Tori Hagel. Osteosarcoma  A malignant tumor of bone in which there is a proliferation of osteoblast.  A type of bone cancer.
The clinical role of PET scanning in GIST Seattle 2007 The clinical role of PET scanning in a consecutive series of GIST patients Department of Surgery.
Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation J Nucl Med 2003; 44:1225–1231 Intern 魏敬庭.
Introduction of Fine Needle Aspiration (for cytotechs) By Dr May Yu 3rd August 07.
NeoTect Tc99m Depreotide Injection. NeoTect  Approved by the FDA - August 3, 1999  Used in Imaging Pulmonary Masses  Normal activity in high concentrations.
Factors Influencing Sarcoma Referral and Treatment William G. Ward, Matthew T. Cline, Fred J. Dorey* Wake Forest University Health Sciences, Winston-Salem,
Verluma Nofetumomab Merpentan (Fragment). Indications For the detection and staging of previously untreated small cell lung cancer. It must be confirmed.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
CONGENITAL NEVI. Common Malignant Neoplasms of Infancy and ChildhoodCommon Malignant Neoplasms of Infancy and Childhood 0 to 4 Years5 to 9 Years10 to.
Screening.  “...the identification of unrecognized disease or defect by the application of tests, examinations or other procedures...”  “...sort out.
CARATTERIZZAZIONE DI LESIONI DI ORIGINE SCONOSCIUTA SOSPETTE PER LESIONI MALIGNE NEI PAZIENTI PEDIATRICI: POSSIBILE RUOLO DEL 18F-FDG PET/CT A.Cistaro.
Introduction to NM Omima Adam NMT 231. What is nuclear medicine NM Is the branch of medicine that uses radiation and nuclear properties of radionuclide's.
Operative Management of Osteosarcoma Patients with Pulmonary Metastasis Jen Kramer, MD R2 Swedish Medical Center February 2011.
Nick Wegner 4/22/10 The Use of CT in Diagnosing Pulmonary Metastases in Osteosarcoma.
J.Calatayud Moscoso del Prado, D.Castellón Plaza, G.Fernández Pérez, N. Silva Priegue, M. Velasco Casares, C. Martínez Rodríguez POVISA Hospital, Vigo.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a complex growth pattern. Imaging plays a crucial role in diagnosis.
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
CT and PET imaging in non-small cell lung cancer
PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,
Figure 3 Risk-adapted and response-adapted
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Dr T P E Wells 13 July 2018 Breast SSG Bath
Pathway for patients with suspected Skin Cancer
Pathway for patients with suspected colorectal cancer
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Introduction of Fine Needle Aspiration (for cytotechs)
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer  Catherine A.B Saunders, Julian.
Evaluation of Average CT to reduce the artifact in PET/CT
(A) Na18F PET images (maximum-intensity projection).
Presentation transcript:

PET/CT AND PAEDIATRIC ONCOLOGY: A SINGLE CENTRE EXPERIENCE A. Cistaro 1, L. Gastaldo 2, A. Brach del Prever 3, V. Arena 1, E. Pelosi 1, M. Mancini 1 CONCLUSIONS in paediatric patients 18F-FDG-PET/CT seems to be useful in metabolic characterisation of suspected tumour and it finds the more accessible active sites for biopsy. In our experience, in patients affected by lymphomas, PET/CT was able to improve staging in 7/11 cases. It seems also useful in re-staging. Nevertheless, because of the high variety of tumour types and the low number of patients analysed, it is necessary to perform further investigations to support these results. MATERIAL AND METHODS 75 patients (age 2-20 years) have been analysed: 12 for metabolic characterisation of lesions of unknown origin suspected for malignant disease, 11 for staging and 52 for re- staging. Whole body PET/CT images were obtained 60 min after the administration of 18F-FDG (3.7 MBq/kg) with Discovery ST (GE Medical Systems). CT was performed with adequate acquisition parameters for paediatrics. AIM To assess the role of FDG-PET/CT in paediatric patients. RESULTS no patient needed sedation during the procedure. In patients analysed for suspected malignant tumour, PET-CT resulted positive in 7 pts (final diagnosis: 2 Autoimmune Lymphoproliferative Syndromes (ALPS) caused by Fas mutation, 2 HL, 2 NHL, 1 ALL), and negative in 5 pts (2 lung aspergillosis, 1 spondilodiscitis, 1 eosinophilic granuloma, 1 lymphadenitis). In positive cases, PET-CT resulted able to indicate the most active and accessible site guiding biopsy. In patient analysed for tumour staging (7 HL and 4 NHL), in 4 cases PET/CT confirmed previous clinical-radiological staging. In 7 cases improved previous staging modifying clinical and therapeutical approach, finding occult tumour sites. SUV measured on first PET/CT exam is important to evaluate chemotherapy effectiveness and for patient’s follow-up. We also analysed 52 patients for re-staging (13 Ewing’s sarcoma,12 osteosarcoma analysed for suspected lung recurrence, 6 rhabdomyosarcoma, 5 NHL, 5 HL, 2 neuroblastoma, 1 Wilm’s tumour, 1 sarcoma of kidney, 3 pNET, 1 adrenal gland carcinoma, 1 undifferentiated hepatic sarcoma, 1 synovial sarcoma, 1epithelioid sarcoma). In 35/52 patients PET/CT correctly confirmed malignancy recurrence, 2 patients resulted false positives (lung flogosis in 2 osteosarcoma patients), 1 false negative (small lung lesion in Ewing’s Sarcoma patient) and 14 true negatives. 1. Positron Emission Tomography IRMET S.p.A., Turin, Italy 2. Department of Paediatric Sciences, Regina Margherita Infant Hospital, Turin, Italy 3. Onco-Hematology Department, Regina Margherita Infant Hospital, Turin, Italy PET-CT resulted able to indicate the most active and accessible site guiding biopsy. Finally diagnosis LNH. Re-staging in epatoblastoma. Hepatic and peritoneal recurrence. Metabolic characterisation of bone e tissue lesions in patient treated for LLA. Finally diagnosis Ewing’s sarcoma Metabolic characterisation of bone lesion. Finally diagnosis eosinophilic granuloma. PET/CT exam allowed to avoid biopsy. For contact: